Unregistered Andrographis capsules and a diabetes medicine claim
A community pharmacy in Siem Reap is offered a consignment of 200 bottles of 'Smau Daek' capsules by a local producer. The label states 500 mg dried Andrographis paniculata extract per capsule and claims 'controls blood sugar, replaces metformin.' The bottles have no batch number, no expiry date, and no MoH registration number. The producer provides a photocopied leaflet describing traditional use for fever and sore throat but no certificate of analysis. A 58-year-old customer with type 2 diabetes, taking metformin 1 g twice daily and glibenclamide 5 mg daily, asks whether she can stop metformin and use these capsules instead. She has a fasting glucose of 9.8 mmol/L and no symptoms of hypoglycemia. The pharmacy has a TLC plate, silica gel, and standard andrographolide reference material, but no HPLC.
1. Assess the quality and regulatory problems with this product. What can the available TLC test establish, and what can it not establish?
Read the worked answer
The product should not be sold. Missing batch number, expiry date, and MoH registration prevent traceability, recall, and assurance of shelf life. The claim 'replaces metformin' is a medicinal claim requiring regulatory review and is clinically dangerous. No certificate of analysis means there are no data on identity, assay, microbial limits, heavy metals, pesticides, or adulteration.
TLC with andrographolide can show a spot consistent with Andrographis and detect some gross adulteration, but it is not quantitative. It cannot prove the label amount, purity, or safety, and it cannot rule out undeclared hypoglycaemic drugs. Organoleptic examination, moisture measurement, macroscopic identity, and a TLC fingerprint are useful supportive checks, but they do not replace full quality control.
Regulatory action: do not stock the consignment; quarantine it; request registration and batch documentation; report illegal claims to the drug regulator if appropriate. A photocopied leaflet is not evidence of quality.
2. Counsel the patient. Address whether she can stop metformin and use the capsules, and what risks matter with her current medicines.
Read the worked answer
She should not stop metformin or substitute these capsules. Her fasting glucose of 9.8 mmol/L is above target and needs prescriber review, not an unproven product. If the capsules actually lower glucose, combining them with glibenclamide increases hypoglycaemia risk; if they are adulterated with a sulfonylurea or another drug, the risk is greater and unpredictable.
She should continue metformin and glibenclamide as prescribed until reviewed, monitor for sweating, tremor, confusion, and hunger, and seek care for symptoms. She should tell her prescriber about any traditional medicine. If she wants herbal treatment, use only a registered product with batch and expiry, and do not replace prescribed therapy.
Document the advice, check her glucose monitoring, and arrange follow-up. Do not dispense the product even if she insists; explain the regulatory and safety reasons plainly.
3. If the pharmacy later wants to stock a registered herbal medicine, outline a due-diligence and pharmacovigilance plan.
Read the worked answer
Verify MoH registration, manufacturer GMP status, batch certificate, expiry, label claims, and permitted indications. Obtain a certificate of analysis for marker content, microbial limits, heavy metals, and pesticides, and retain a sample. Train staff on the evidence and potential interactions, especially with diabetes and anticoagulant medicines.
Record sales and ask patients about prescription medicines. Advise patients not to replace prescribed therapy. Set up an adverse-event log and report suspected reactions to the national pharmacovigilance system. Review stock monthly for expiry. Do not accept practitioner samples without documentation. This plan protects patients and the pharmacy's licence.